Skip to content

Safety of Joint Support Product in knee osteoarthritis

Evaluation of the efficacy and safety of Joint Support Product (GP/PROD/2021/002) in knee osteoarthritis: A randomized, double-blind, Placebo controlled clinical study. - Nil

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039176
Enrollment
150
Registered
2022-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Joint Support Product (GP/PROD/2021/002): 2 tablets twice a day after meals for 3 months. Control Intervention1: Placebo tablets: 2 tablets twice a day after meals for 3 months.

Sponsors

Mr Kamlesh Thummar
Lead Sponsor
Mr Pritesh Shah
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Male and/or female volunteers aged between 40 to 80 years both inclusive. BMI ( �) greater than or equal to 24 Kg/m2 and less than or equal to (�) 38 Kg/m2 Willing to follow the diet advised by investigator Willing to come for regular follow-up visits. Patients diagnosed clinically with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria.

Exclusion criteria

Exclusion criteria: Patients with congenital arthropathy, rheumatoid arthritis, active gout, other type of arthritis with/without inflammation e.g. septic, fibromyalgia or collagen vascular disease Patients with known history of coagulopathies Osteoarthritis of any other joint except knee Patients with history of major trauma or surgery in the knee joint Patients with uncontrolled diabetes and hypertension Body mass index (BMI) >38 kg/m2. Patients with any severe cardiac, renal and hepatic disease Pregnant and lactating women Patients who participated in any clinical trial within 30 days before enrollment into the study Any other condition which the Principal Investigator thinks may jeopardize the study

Design outcomes

Primary

MeasureTime frame
Changes in levels of inflammatory mediators CRP, IL-6 Assessment of performance of patient on pain VAS scale. Local examination, clinical signs Assessment of WOMACTimepoint: Screening Day , Baseline Day, Day 30 , Day 60, Day 90

Secondary

MeasureTime frame
Symptom improvement like morning sickness, tiredness, tenderness, and muscle spasms Assessment in Improvement in quality of life score Reduction in requirement of rescue analgesicsTimepoint: Screening Day , Baseline Day, Day 30 , Day 60, Day 90

Countries

India

Contacts

Public ContactMr Chetan savaliya

Gplife Healthcare Pvt Ltd

gplifehealthcare@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026